Francisco Cezar Aquino de Moraes, Pedro Henrique de Souza Wagner, Isabella Christina Amaral de Lara, Barbara Lins Silva, Ana Laura Soares Silva, Artur de Oliveira Macena Lôbo, Luana Izabela Azevedo de Carvalho, Michele Kreuz, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano
{"title":"他汀类药物与女性乳腺癌预后：荟萃分析。","authors":"Francisco Cezar Aquino de Moraes, Pedro Henrique de Souza Wagner, Isabella Christina Amaral de Lara, Barbara Lins Silva, Ana Laura Soares Silva, Artur de Oliveira Macena Lôbo, Luana Izabela Azevedo de Carvalho, Michele Kreuz, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano","doi":"10.1007/s12094-025-03935-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) incidence is estimated to achieve over 3-million new cases and one million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescribed for managing cardiovascular health, have garnered attention for their potential role in breast cancer management. Emerging evidence suggests that statins possess anti-proliferative properties, which could impact BC progression. Understanding the potential benefits of statin therapy in BC patients is crucial for optimizing treatment strategies and improving outcomes.</p><p><strong>Methods: </strong>Hazard ratio (HR) with 95% confidence intervals (CIs) were calculated to evaluate the outcomes. The DerSimonian and Laird random-effects model was used for all pooled analyses. Heterogeneity was assessed using the I<sup>2</sup> statistic with corresponding 95% CIs, considering I<sup>2</sup> > 25% as indicative of substantial heterogeneity. Statistical analyses were conducted in R (version 4.3.2) using the \"meta\" package, with a significance level set at P < 0.05.</p><p><strong>Results: </strong>A total of 31 studies and 344,936 patients were included, of whom 72,784 (21.1%) was in the statins group and 272,152 (78.9%) was in the non-statin users group. Statin therapy was associated with a significantly reduced risks of all-cause mortality (HR 0.8583; 95% CI 0.7980-0.9231; P < 0.001; I<sup>2</sup> = 81.1%), of BCSM (HR 0.8183; 95% CI 0.7334-0.9132; P < 0.001; I<sup>2</sup> = 84.4%), and of BC recurrence (HR 0.7911; 95% CI 0.6882-0.9095; P < 0.001; I<sup>2</sup> = 48.6%). However, the analysis of DFS did not show a statistically significant difference between the groups (HR 0.8415; 95% CI 0.4220-1.6780; P = 0.624; I<sup>2</sup> = 74.2%).</p><p><strong>Conclusion: </strong>Our meta-analysis suggests that statin therapy may confer beneficial effects on clinical outcomes in female breast cancer patients, including reduced all-cause mortality, breast cancer-specific mortality, and recurrence. However, further research is warranted to confirm these findings and elucidate the mechanisms underlying these associations.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3886-3901"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Statins and prognosis of female breast cancer: a meta-analysis.\",\"authors\":\"Francisco Cezar Aquino de Moraes, Pedro Henrique de Souza Wagner, Isabella Christina Amaral de Lara, Barbara Lins Silva, Ana Laura Soares Silva, Artur de Oliveira Macena Lôbo, Luana Izabela Azevedo de Carvalho, Michele Kreuz, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano\",\"doi\":\"10.1007/s12094-025-03935-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Breast cancer (BC) incidence is estimated to achieve over 3-million new cases and one million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescribed for managing cardiovascular health, have garnered attention for their potential role in breast cancer management. Emerging evidence suggests that statins possess anti-proliferative properties, which could impact BC progression. Understanding the potential benefits of statin therapy in BC patients is crucial for optimizing treatment strategies and improving outcomes.</p><p><strong>Methods: </strong>Hazard ratio (HR) with 95% confidence intervals (CIs) were calculated to evaluate the outcomes. The DerSimonian and Laird random-effects model was used for all pooled analyses. Heterogeneity was assessed using the I<sup>2</sup> statistic with corresponding 95% CIs, considering I<sup>2</sup> > 25% as indicative of substantial heterogeneity. Statistical analyses were conducted in R (version 4.3.2) using the \\\"meta\\\" package, with a significance level set at P < 0.05.</p><p><strong>Results: </strong>A total of 31 studies and 344,936 patients were included, of whom 72,784 (21.1%) was in the statins group and 272,152 (78.9%) was in the non-statin users group. Statin therapy was associated with a significantly reduced risks of all-cause mortality (HR 0.8583; 95% CI 0.7980-0.9231; P < 0.001; I<sup>2</sup> = 81.1%), of BCSM (HR 0.8183; 95% CI 0.7334-0.9132; P < 0.001; I<sup>2</sup> = 84.4%), and of BC recurrence (HR 0.7911; 95% CI 0.6882-0.9095; P < 0.001; I<sup>2</sup> = 48.6%). However, the analysis of DFS did not show a statistically significant difference between the groups (HR 0.8415; 95% CI 0.4220-1.6780; P = 0.624; I<sup>2</sup> = 74.2%).</p><p><strong>Conclusion: </strong>Our meta-analysis suggests that statin therapy may confer beneficial effects on clinical outcomes in female breast cancer patients, including reduced all-cause mortality, breast cancer-specific mortality, and recurrence. However, further research is warranted to confirm these findings and elucidate the mechanisms underlying these associations.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"3886-3901\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-03935-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03935-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：到2040年，乳腺癌（BC）的发病率估计将达到300多万新病例和100万死亡病例。除了身体上的伤害，乳腺癌还会对生活质量造成不利影响，给患者及其家庭带来情感、社会和经济负担。他汀类药物通常用于管理心血管健康，因其在乳腺癌管理中的潜在作用而引起了人们的关注。新出现的证据表明他汀类药物具有抗增殖特性，这可能影响BC的进展。了解他汀类药物治疗BC患者的潜在益处对于优化治疗策略和改善预后至关重要。方法：计算风险比（HR）和95%可信区间（ci），评价结果。所有合并分析均采用DerSimonian和Laird随机效应模型。异质性评估采用I2统计量，相应ci为95%，认为I2 >为25%，表明存在显著异质性。在R（4.3.2版本）中使用“meta”软件包进行统计分析，显著性水平为P。结果：共纳入31项研究，344,936例患者，其中他汀类药物组72,784例（21.1%），非他汀类药物组272,152例（78.9%）。他汀类药物治疗与全因死亡风险显著降低相关(HR 0.8583；95% ci 0.7980-0.9231；P 2 = 81.1%), BCSM (HR 0.8183；95% ci 0.7334-0.9132；P 2 = 84.4%)和BC复发率(HR 0.7911；95% ci 0.6882-0.9095；p 2 = 48.6%)。然而，DFS分析显示两组间差异无统计学意义(HR 0.8415；95% ci 0.4220-1.6780；p = 0.624；i2 = 74.2%)。结论：我们的荟萃分析表明，他汀类药物治疗可能对女性乳腺癌患者的临床结果产生有益的影响，包括降低全因死亡率、乳腺癌特异性死亡率和复发率。然而，需要进一步的研究来证实这些发现并阐明这些关联的机制。
Statins and prognosis of female breast cancer: a meta-analysis.
Background: Breast cancer (BC) incidence is estimated to achieve over 3-million new cases and one million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescribed for managing cardiovascular health, have garnered attention for their potential role in breast cancer management. Emerging evidence suggests that statins possess anti-proliferative properties, which could impact BC progression. Understanding the potential benefits of statin therapy in BC patients is crucial for optimizing treatment strategies and improving outcomes.
Methods: Hazard ratio (HR) with 95% confidence intervals (CIs) were calculated to evaluate the outcomes. The DerSimonian and Laird random-effects model was used for all pooled analyses. Heterogeneity was assessed using the I2 statistic with corresponding 95% CIs, considering I2 > 25% as indicative of substantial heterogeneity. Statistical analyses were conducted in R (version 4.3.2) using the "meta" package, with a significance level set at P < 0.05.
Results: A total of 31 studies and 344,936 patients were included, of whom 72,784 (21.1%) was in the statins group and 272,152 (78.9%) was in the non-statin users group. Statin therapy was associated with a significantly reduced risks of all-cause mortality (HR 0.8583; 95% CI 0.7980-0.9231; P < 0.001; I2 = 81.1%), of BCSM (HR 0.8183; 95% CI 0.7334-0.9132; P < 0.001; I2 = 84.4%), and of BC recurrence (HR 0.7911; 95% CI 0.6882-0.9095; P < 0.001; I2 = 48.6%). However, the analysis of DFS did not show a statistically significant difference between the groups (HR 0.8415; 95% CI 0.4220-1.6780; P = 0.624; I2 = 74.2%).
Conclusion: Our meta-analysis suggests that statin therapy may confer beneficial effects on clinical outcomes in female breast cancer patients, including reduced all-cause mortality, breast cancer-specific mortality, and recurrence. However, further research is warranted to confirm these findings and elucidate the mechanisms underlying these associations.
期刊介绍：
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
